Trial Profile

A Drug-Drug Interaction Study of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 4646 (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide; Dolutegravir
Indications HIV-1 infections
Focus Pharmacokinetics
Sponsors Merck & Co

Most Recent Events

21 Apr 2026 New trial record
20 Apr 2026 Planned End Date changed from 13 Jul 2026 to 21 Jul 2026.
20 Apr 2026 Planned primary completion date changed from 13 Jul 2026 to 21 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com